Bioceres Crop Solutions Corp.

Bioceres Crop Solutions Corp.

BIOX
Bioceres Crop Solutions Corp.US flagNASDAQ Global Select
0.38
USD
+0.00
- -
23.94MMarket Cap
2018 Y
2018 Y
2019 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
2026 Y
TTM
Revenue per Share
- -
4.75
- -
5.26
4.77
5.27
7.76
6.75
7.4
5.27
- -
2.98
Basic EPS, GAAP
- -
-0.39
0.23
-0.6
0.09
-0.18
-0.17
0.3
0.07
-0.88
- -
-3.14
Free Cash Flow per Basic Share
- -
0.53
-0.31
0.88
0.17
-0.41
-0.51
-0.15
0.49
0.69
- -
0.49
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
- -
0.95
8.22
1.31
1.28
1.65
2.78
4.76
5.2
4.16
- -
- -
Tangible Book Value per Share
- -
-1.9
8.22
-0.61
-0.41
-0.69
0.32
0.21
0.43
-0.48
- -
- -
Basic Weighted Avg Shares
- -
28
3
30
36
39
42
62
63
63
64
64
Sales/Revenue/Turnover
- -
133
- -
160
172
207
328
419
465
333
- -
189
Operating Margin (%)
- -
13.37
- -
19.38
22.15
18.36
13.46
12.69
9.48
-0.23
- -
5.7
Depreciation Expense
- -
4
- -
5
5
6
9
19
21
22
- -
7
Net Income, GAAP
- -
-11
1
-18
3
-7
-7
19
4
-55
- -
-199
Effective Tax Rate (%)
- -
- -
- -
- -
34.25
136.28
127.79
- -
34.14
- -
- -
- -
Profit Margin (%)
- -
-8.27
- -
-11.46
1.95
-3.32
-2.19
4.48
0.92
-16.62
- -
-105.31
Working Capital
- -
-33
- -
-18
34
43
75
98
79
-30
- -
- -
LT Debt
- -
26
- -
37
85
97
97
146
131
48
- -
- -
Total Equity
- -
33
118
62
61
90
158
330
351
295
- -
- -
Return on Invested Capital (%)
- -
- -
-0.82
- -
13.55
-5.82
-4.14
- -
4.82
- -
- -
- -
Return on Capital (%)
- -
- -
0.61
- -
8.12
-7.07
-4.94
- -
2.83
- -
- -
- -
Return on Common Equity (%)
- -
-160.86
1.13
-22.19
7.19
-12.06
-7.37
8.81
1.39
-19.17
- -
-151.72

Capital Structure

FRC

•

in mil. unless spec.
Dec'26
Mar'26
Jun'26
ST Debt
197
177
- -
LT Borrowings
34
54
- -
LT Finance Leases
8
9
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
64
64
64
Market Capitalization
84
28
22

Working Capital

FRC

•

in mil. unless spec.
Dec'26
Mar'26
Jun'26
Total Current Assets
294
261
- -
Cash, Cash Equivalents & STI
13
15
- -
Accounts Receivable, Net
155
136
- -
Inventories
67
53
- -
Total Current Liabilities
329
298
- -
Payables & Accruals
96
84
- -
ST Debt
197
177
- -
Deferred Revenue
2
3
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
- -
Free Cash Flow
- -
- -
- -
Net Income, GAAP
- -
- -
- -
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
116
140
84
124
465
2025
93
99
50
74
333
2026
77
74
38
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.07
- -
0.15
-0.02
0.07
2025
-0.1
- -
0.04
-0.76
-0.88
2026
-0.12
-2.88
-0.14
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

CEO
Federico Trucco
Full Time Employees
751
Sector
Basic Materials
Industry
Agricultural Inputs
Address
Ocampo 210 bis Rosario SF Argentina 2000
IPO Date
Mar 22, 2018
Business
Bioceres Crop Solutions Corp. provides crop productivity solutions through its Seed and Integrated Products, Crop Protection, and Crop Nutrition segments; offers seed traits, germplasms, seed treatment packs, HB4 drought-tolerant seed technology for soybeans and wheat, Rizoderma, adjuvants, therapies, herbicides, insecticides, fungicides, baits, inoculants, bio-inductors, biological and microgranulated fertilizers; founded in 2001 and headquartered in Rosario, Argentina. The company operates in over 40 countries, primarily Argentina, Brazil, the United States, Europe, and South Africa, targeting growers with biotech platforms for higher yields and climate resilience. Recent developments include a strategic agreement with GDM for new soybean solutions with exclusive rights outside drought tolerance, redefinition of its wheat joint venture with Florimond Desprez by exiting conventional breeding in Argentina and Australia while licensing HB4 wheat technology elsewhere, and a merger with Moolec Science, Nutrecon, and Gentle Tech to form a diversified agtech entity with over 800 patents and expanded regenerative agriculture offerings.

Company News

  • Bioceres Crop Solutions Corp. (BIOX) Q4 2026 Earnings Call Transcript

  • Bioceres Crop Solutions Reports Fiscal Fourth Quarter and Full-Year 2026 Financial and Operating Results

  • Bioceres Crop Solutions to Host Fiscal Fourth Quarter and Full Year 2026 Financial Results Conference Call on Tuesday, September 15, 2026 at 8:30 a.m. Eastern Time

  • Pinnacle Food Group (NASDAQ:PFAI) vs. Bioceres Crop Solutions (NASDAQ:BIOX) Head to Head Contrast

  • Bioceres Crop Solutions Corp. (BIOX) Q3 2026 Earnings Call Transcript

  • Bioceres Crop (BIOX) Reports Q3 Loss, Misses Revenue Estimates

  • Bioceres Crop Solutions Reports Fiscal Third Quarter 2026 Financial and Operational Results

  • CORRECTING and REPLACING Bioceres Crop Solutions to Host Fiscal Third Quarter 2026 Financial Results Conference Call on Tuesday, May 12, 2026 at 8:30 a.m. Eastern Time

  • Bioceres Crop Solutions to Host Fiscal Third Quarter 2026 Financial Results Conference Call on Tuesday, May 12, 2026 at 8:30 a.m. Eastern Time

  • Bioceres Crop Solutions (NASDAQ:BIOX) and Lavoro (NASDAQ:LVRO) Financial Comparison

  • Head-To-Head Review: Bioceres Crop Solutions (NASDAQ:BIOX) and Moolec Science (NASDAQ:MLEC)

  • Analyzing Bioceres Crop Solutions (NASDAQ:BIOX) & Davis Commodities (NASDAQ:DTCK)

  • A Message from Our Chief Executive Officer

  • Bioceres Crop Solutions Corp. (NASDAQ:BIOX) Short Interest Up 71.0% in February

  • Bioceres Crop Solutions Corp. (NASDAQ:BIOX) Receives $4.00 Consensus Price Target from Brokerages

  • Bioceres Crop Solutions Corp. (BIOX) Shareholder/Analyst Call Prepared Remarks Transcript

  • Analysts Set Bioceres Crop Solutions Corp. (NASDAQ:BIOX) Target Price at $4.00

  • Bioceres Crop Solutions (NASDAQ:BIOX) vs. Brasilagro Cia Brasileira De Propriedades Agricolas (NYSE:LND) Financial Analysis

  • Bioceres Crop Solutions Corp. (NASDAQ:BIOX) Receives $4.08 Consensus Price Target from Analysts

  • Bioceres Lenders Claim Default, And Dilution Risks Are Higher Than Ever